search 


  home about us creating value our technologies pipeline news & events

studies

  site map
   
 

AAO-HNSF 2010
September 26-29, 2010
Boston, Massachusetts

NACFC 2010
October 21-23, 2010
Baltimore, Maryland

  PARI nebulizers are considered the gold standard for clinical trials, and recommended in commercial sales including:

Pulmicort® (AstraZeneca)
Xopenex® (Sepracor)

Perforomist (Dey)
Brovana (Sepracor)

PARI nebulizers are the gold standard in inhalation therapy.

 

The future of effective aerosol therapies lies in the optimization of drug-to-device and device-to-drug.
PARI Pharma has taken the next step and combined formulation development, next generation aerosol platforms, and aerosol characterization under one roof.


We are currently working with both the eFlow® Technology (lower respiratory) and Vibrent Technology (upper respiratory) Advanced Aerosol delivery platforms.

This multifunctional development program is the key to creating targeted therapies with high deposition amounts, low side-effect profiles, improved patient compliance…and better controlled, healthier patients.

After 100 years, we know aerosol science and aerosol delivery.
 

 

 

Partner Press Release:

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its head-to-head Phase III clinical trial of Cayston® (aztreonam for inhalation solution) versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa) achieved one of its co-primary endpoints of non-inferiority for mean percent change in forced expiratory volume in one second (FEV1) percent predicted after 28 days of treatment. [more]

- - - - - - - - - - - - - - - -

Partner Press Release:

Transave, Inc., today reported interim results from a multi-cycle Phase II open label clinical trial in cystic fibrosis (CF) patients on its lead investigational drug, ARIKACETM (liposomal amikacin for inhalation). [more]

- - - - - - - - - - - - - - - -

Partner Press Release

Transave Inc. today announced that the United States Patent and Trademark Office has issued an important composition of matter patent (U.S. Patent No. 7,718,189) for liposomal aminoglycoside formulations including its lead compound, ARIKACE™ (liposomal amikacin for inhalation). [more]

 
     home  |  about us  |  creating value  |  our technologies  |  pipeline  |  news & events  |  studies

     © 2006-2008 PARI GmbH. All Rights Reserved.


PARI - 100 Years - Specialists in effective inhalation